Reuters -- Astellas Pharma Inc, Japan’s second-largest drugmaker, said on Tuesday it has won approval to sell its key transplant drug Prograf in Japan as a treatment for severe ulcerative colitis, a form of intestinal inflammation.
Reuters -- Astellas Pharma Inc, Japan’s second-largest drugmaker, said on Tuesday it has won approval to sell its key transplant drug Prograf in Japan as a treatment for severe ulcerative colitis, a form of intestinal inflammation.
